What Monomax SR Treats: Main Uses and Benefits

Monomax SR (Isosorbide Mononitrate Extended-Release) is commonly used for the prophylactic management of symptoms related to Coronary Artery Disease (CAD). Its role is to provide supportive relief on a long-term basis, relevant when supportive symptom management is appropriate. It is applied in clinical settings that involve acute or unstable symptom patterns, consistent with its therapeutic domain.

This therapy is primarily relevant for easing symptoms associated with Chronic Angina Pectoris and may assist with maintaining functional stability when symptoms interfere with routine activities. The therapeutic benefit may help ease the overall symptom burden of these recurrent manifestations over time, supporting a sense of stability when symptoms are more noticeable. It may support patients during symptomatic phases, and is relevant for managing the pattern of episodic manifestations.

“This approach is relevant when supportive symptom management is appropriate and contributes to easing the overall symptom load.”

---

Quick Fact: Symptomatic Support for Recurrent Chest Discomfort Monomax SR is commonly used to help with the symptoms related to chronic angina pectoris and may support patients during symptomatic phases.

---

Regulatory References

1. NIH StatPearls overview

Monomax SR is intended primarily for adult patients for whom the medicine is indicated. Official regulatory documents define clear population-based rules regarding who can and cannot use this medication.

---

Absolute Contraindications

The medicine must not be used by patients with a known hypersensitivity to isosorbide mononitrate or any other nitrate. Coadministration with Phosphodiesterase-5 (PDE-5) inhibitors (such as sildenafil) or the sGC stimulator riociguat is absolutely contraindicated due to the risk of severe hypotension.

---

Population and Condition Restrictions

Monomax SR is not recommended in the setting of recent acute myocardial infarction (MI) or congestive heart failure (CHF), as the prolonged-release nature makes the drug's effects difficult to manage in acute settings. Use requires caution in patients with hypotension or volume depletion, and in those with hypertrophic cardiomyopathy. The drug is not suitable for treating acute anginal episodes.

---

Age and Organ Function Eligibility

Safety and efficacy are not established in the pediatric population (under 18 years of age). For adults with renal impairment or hepatic impairment, no specific dose adjustment is necessary. During pregnancy and lactation, use is approached with caution; the benefit must outweigh the potential risk, and excretion into breast milk is unknown.

Monomax SR Interactions with other medicines and products

The official regulatory profile for Monomax SR (Isosorbide Mononitrate) defines interactions primarily based on potential pharmacodynamic effects, particularly the risk of additive vasodilation and amplified blood pressure reduction.

Co-administration with the following specific drug classes is formally contraindicated due to the documented high risk of severe hypotension, syncope, or myocardial ischemia:

Category	Example Agents
PDE5 Inhibitors	Sildenafil, Tadalafil, Vardenafil, Avanafil
sGC Stimulators	Riociguat

The hypotensive effect of Monomax SR may be potentiated by co-administration with other agents that lower blood pressure, including Calcium Channel Blockers, Beta-blockers, ACE Inhibitors, Angiotensin II Receptor Antagonists, and certain Neuroleptics or Tricyclic Antidepressants.

Regarding other substances, alcohol exhibits additive vasodilatory effects that can increase the potential for postural hypotension. While food intake may decrease the rate of absorption for extended-release formulations, the overall amount of medication absorbed remains unchanged. Aspirin or Acetaminophen co-administration is officially documented as having no deleterious effect on the antianginal efficacy of the product. Furthermore, clinical experience notes that elderly patients may exhibit an increased sensitivity to the effects of organic nitrates, which is a specific consideration when combining with other interacting agents.

Nitric Oxide Release and Vascular Dilation

This mechanism involves the drug being metabolized to release Nitric Oxide (NO), a chemical signal that activates the cGMP signaling pathway inside vascular smooth muscle cells. NO is a gaseous mediator that binds to and activates the enzyme soluble Guanylate Cyclase (sGC). The resulting molecular cascade raises the intracellular concentration of cyclic GMP (cGMP), which triggers the dephosphorylation of myosin light chains. This action leads to the relaxation and widening of blood vessel walls, which is the primary physical action of the drug.

---

Modulation of Cardiac Workload

The widespread widening of the blood vessels, particularly the venous capacitance vessels, results in a decrease in the amount of blood returning to the heart, thereby reducing the preload. By easing both the volume and the pressure the heart must pump against (afterload), the mechanism produces physiological changes that alter the balance between myocardial oxygen supply and demand.

Official Administration Guidelines for Monomax SR

Monomax SR (isosorbide mononitrate prolonged-release) is an oral medication that must be used strictly according to the prescribing information to ensure proper functioning and effectiveness. The administration method is designed to provide a specific daily drug-free period.

Administration Scope	Detail
Route	Oral use
Frequency	Once daily
Timing	Should be taken in the morning (upon waking) to allow for the required daily drug-free interval.
With Food	May be taken with or without food

Dosing and Preparation

The usual adult dose is one 60 mg prolonged-release tablet once daily. The dosage may be increased up to a maximum of 120 mg once daily. To minimize certain side effects, initial treatment may begin with a 30 mg dose (half of a scored 60 mg tablet) daily for the first two to four days.

The tablet must be swallowed whole with a glass of water. It must not be crushed, chewed, or divided (unless starting at the 30 mg dose, if scored, and then swallowed whole) to preserve its extended-release properties.

Procedural and Age-Specific Rules

• Missed Dose: If a dose is missed, it should be taken as soon as remembered. However, if it is almost time for the next dose, the missed dose must be skipped, and the regular schedule continued. Do not take double or extra doses.
• Acute Relief: This medication is not indicated for the relief of an acute event; fast-acting medicine must be used for acute symptoms.
• Children and Elderly: The medication is generally not for use in children. A lower dose may be prescribed for elderly patients.

Research Evidence: Overview of Studies for Monomax SR

This overview describes the types of clinical research that have been conducted for Monomax SR (isosorbide mononitrate extended-release), detailing what the studies examined and where the research base still has limitations. The information presented here summarizes findings observed in groups of patients during clinical trials and is not a prediction of individual outcomes.

---

Evidence for the Prophylaxis of Chronic Angina Pectoris

This section summarizes the structure of the key Randomized Controlled Trials (RCTs) and controlled clinical studies that were evaluated in research exploring the prophylaxis of chronic stable chest pain. The primary evidence for this medicine comes from controlled research, including trials that compared the agent to an inactive treatment (placebo). These studies were applied in research contexts involving conditions characterized by fluctuating or episodic manifestations of chest discomfort.

In these trials, research examined functional measures including total exercise capacity on a treadmill and the time it took for the onset of physical discomfort (angina) during the activity. Studies also monitored physiological strain by measuring the time to specific cardiac markers during exertion. Findings describe patterns observed in the studies over the defined time intervals. Research highlights measured differences during the study period, particularly in the hours immediately following the dose, related to functional capacity when compared to the placebo group.

---

Long-Term Studies and Durability of Effect

This part will detail the observation periods and follow-up durations used in the main clinical research, including the intermediate-term studies (e.g., up to six weeks). It will also summarize the scope and conclusions of research examining effect maintenance when continuous administration was studied over time.

The majority of clinical data for Monomax SR was evaluated in studies with short to intermediate follow-up durations, typically extending up to six weeks of continuous administration. The available research base notes that long-term patterns of change are not fully established beyond these intermediate follow-up durations.

---

Understanding Research Gaps and Uncertainty

Comparative evidence is limited regarding its application during acute heart events, as the primary research focus was strictly prophylactic. Therefore, there is limited information regarding the use of this sustained-release formulation for treating or stopping a sudden, acute episode of chest pain or for other life-threatening heart conditions. Ultimately, the evidence highlights what is known—and what is still uncertain—about this agent.

Key Studies & References

1. Isosorbide Mononitrate

Common questions about Monomax SR (FAQ)

---

Q: What is the purpose of the slow-release (SR) formulation?

A: The extended-release (SR) formulation is designed to release the medication gradually over a prolonged period. This controlled release is intended to provide a prolonged therapeutic level of the drug. Official information notes that this design also ensures the required daily drug-free interval, which is important to help prevent the body from developing tolerance to the medication's effects.

---

Q: Why would someone switch from a different nitrate drug to Monomax SR?

A: The active ingredient in this formulation, isosorbide mononitrate, is delivered in a way that allows for once-daily dosing. The single daily dose allowed by the extended-release formulation may be considered a practical advantage compared to some other nitrate preparations that require more frequent dosing.

---

Q: Are there any known interactions between Monomax SR and herbal supplements?

A: Regulatory-backed sources provide limited specific information on interactions between Monomax SR and various herbal supplements. Patients are generally advised to inform their healthcare provider about all supplements, remedies, and vitamins they are using.

---

Q: How long after taking Monomax SR is the maximum effect reached?

A: Monomax SR is a sustained-release medicine, meaning it is not designed for a rapid effect. Official pharmacokinetic data indicates that the maximum concentration of the drug in the bloodstream (known as peak plasma concentration) is typically reached a few hours after the tablet is taken. The formulation is designed to prolong the therapeutic levels of the drug.

---

Q: What are the serious, but less common, side effects of Monomax SR?

A: Serious, but less common, effects reported in official documentation include syncope (fainting) secondary to low blood pressure. Rarely, more general reactions such as itching (pruritus) or muscle pain (myalgia) have been documented. Information on potential serious events is provided in the official documentation.

---

Q: Is Monomax SR suitable for people with kidney problems?

A: Official drug information indicates that for most adults with renal impairment (kidney problems), no specific dose change is considered necessary. However, caution is noted in official documentation for use in patients with pre-existing severe kidney disease due to the potential for the medication to lower blood pressure (hypotension).

---

Q: What is the typical half-life of Monomax SR?

A: The half-life refers to the time it takes for half of the active drug to be cleared from the body. Official pharmacokinetic data indicates that the mean plasma elimination half-life of the active ingredient (Isosorbide Mononitrate) is typically about five hours for both sustained-release and immediate-release formulations.

---

Q: Are there generic versions of Monomax SR available?

A: Yes, official drug registries confirm that the active ingredient, Isosorbide Mononitrate extended-release oral tablet, has approved generic versions. These generic versions are officially approved.

---

Q: Does Monomax SR cause a drop in blood pressure in healthy people?

A: As a vasodilator, Monomax SR works by relaxing blood vessels, which leads to lower blood pressure (hypotension). Consistent with its pharmacological mechanism, the drug is known to have a blood pressure-lowering effect which is not limited to patients with existing high blood pressure.

---

Q: How does Monomax SR compare to nitroglycerin patches?

A: Both Monomax SR and nitroglycerin patches are long-acting nitrates used for the prophylactic prevention of angina episodes. The primary distinction is the route of administration: Monomax SR is an oral medication, while nitroglycerin patches are applied to the skin (transdermal delivery).

---

Q: Does Monomax SR affect kidney function?

A: The active ingredient does not appear to directly impair kidney function in the majority of patients, and according to official information, no specific dose adjustment is considered necessary for renal impairment. Nevertheless, official caution is advised for individuals with existing severe renal disease.

---

Q: Why is Monomax SR considered a prophylactic treatment?

A: Monomax SR is classified as a prophylactic (preventative) treatment because its action is not rapid enough to stop a sudden anginal episode once it has started. It is prescribed for regular use with the aim of reducing the incidence of future attacks, as it is not formulated to provide immediate relief for an acute event.

---

Q: Is Monomax SR a beta-blocker or a calcium channel blocker?

A: No, Monomax SR is not a beta-blocker or a calcium channel blocker. It belongs to a separate class of medicines called Organic Nitrates and is classified as an Antianginal Agent. It works specifically by relaxing the blood vessel walls.

---

Q: Does taking Monomax SR mean I can stop using my emergency rescue spray?

A: No. Official patient information is clear that Monomax SR is only for prevention of angina, not for immediate relief. Therefore, patients typically need to continue carrying and using a prescribed fast-acting nitrate for immediate relief of sudden chest pain.

---

Q: What happens if Monomax SR is taken too close to another heart medicine?

A: Taking Monomax SR with other medications that lower blood pressure, such as certain beta-blockers or calcium channel blockers, can potentiate (increase) the hypotensive effect. The heightened effect carries a risk of increased dizziness or fainting.

Official Storage and Disposal Requirements

Storage and disposal instructions for Monomax SR (Isosorbide Mononitrate Extended-Release) are strictly defined by regulatory documents to maintain medication integrity and safety.

Requirement	Official Instructions
Temperature	Store at Controlled Room Temperature, typically 15 C to 30 C (59 F to 86 F).
Protection	Keep the medication in its original, tightly closed container. Protect from excessive moisture, humidity, and heat. Do not freeze.
Handling	Do not crush, chew, or divide the tablets/capsules.
Child Safety	Store strictly out of the reach of children.
Disposal	Dispose of unused or expired Monomax SR through an official medicine take-back program or as directed by a healthcare professional. Avoid flushing the medication down the toilet or placing it in household trash to prevent environmental contamination.